P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

• Alan Skarbnik,
• Adam Kittai,
• Miguel Miranda,
• Alan Yong,
• Jack Roos,
• Robert Hettle,
• Sarah Palazuelos-Munoz,
• Vikram Shetty,
• Paolo Ghia

Affiliations

Alan Skarbnik

1 Novant Health Cancer Institute, Lymphoma and CLL program, Charlotte, United States

Adam Kittai

2 The Ohio State University Comprehensive Cancer Center, Division of Hematology, Columbus, United States

Miguel Miranda

3 AstraZeneca, Cambridge, United Kingdom

Alan Yong

4 AstraZeneca, Wilmington, United Kingdom

Jack Roos

5 AstraZeneca, 1800 Concord Pike, Wilmington, United States

Robert Hettle

3 AstraZeneca, Cambridge, United Kingdom

Sarah Palazuelos-Munoz

5 AstraZeneca, 1800 Concord Pike, Wilmington, United States

Vikram Shetty

3 AstraZeneca, Cambridge, United Kingdom

Paolo Ghia

6 5Università Vita-Salute San Raffaele, Milan, Italy